{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0013697\nAge: 76\nGender: Male\nSample ID: P-0013697-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Prostate Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 60.0%\n=============\nDNA Variants:\nANKRD11 c.2534T>A (p.L845*) - in 46.00% of 1247 reads\nCDKN2C c.224A>G (p.H75R) - in 42.00% of 625 reads\nMYOD1 c.308G>A (p.R103H) - in 33.00% of 265 reads\nPTPRD c.143C>T (p.T48M) - in 45.00% of 565 reads\nCNA Data:\nAR - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer\",\n    \"Disease Phase or Condition\": \"Metastatic castration resistant prostate cancer (mCRPC)\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n    \"Genomic Features\": [\n      \"CHEK1\",\n      \"BRIP1\",\n      \"RAD51C\",\n      \"RAD51D\",\n      \"RAD51B\",\n      \"RAD54L\",\n      \"ATM\",\n      \"CHEK2\",\n      \"BARD1\"\n    ],\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Solid Tumor\",\n    \"Disease Phase or Condition\": \"Unresectable or metastatic MSI-high solid tumors\",\n    \"Drug Name\": \"Pembrolizumab\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment, no satisfactory alternative options\",\n    \"Genomic Features\": [\n      \"MSI-high\"\n    ],\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n  }\n}"
}